Pipeline

Denifanstat Pipeline on Multiple Indications and Clinical Milestones

Stage of Development

Therapeutic area

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

Metabolic disease

TVB-2640
TVB-3567

Dermatology

TVB-2640 (ASC40)*

Oncology

TVB-2640 (ASC40)*

* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China